Streetbeat News

Stock Prices

TXT

Over the past 15 years, Textron (NYSE:TXT) has produced an average annual return of 23.02%, outperforming the market by 8.66%. A $1000 investment in TXT 15 years ago would be worth $23,749.33 today. Textron's market capitalization currently stands at $17.18 billion.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

SHLS

Shoals Technologies Gr (NASDAQ:SHLS) has been the subject of 12 analyst reviews over the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is now $19.33, a 20.06% decrease from the previous $24.18. Analysts from firms like Goldman Sachs, Cantor Fitzgerald, and JP Morgan have lowered their price targets, reflecting adjustments to market conditions and company performance. Despite a positive revenue trend with a 47.77% growth rate as of September 30, 2023, SHLS faces challenges in market capitalization, ROE, and ROA, positioning below industry averages.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

TRGP

Targa Resources (NYSE:TRGP) has delivered an average annual return of 19.21% over the past 5 years, outperforming the market by 6.38%. An investment of $100 in TRGP 5 years ago would be worth $238.54 today. The company currently has a market capitalization of $21.92 billion.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

CERT

Certara (NASDAQ:CERT) received mixed analyst ratings with 4 indifferent ratings in the past three months. The average 12-month price target is $17.38, up from $15.00, indicating a 15.87% increase. Analysts from Jefferies, Leerink Partners, Barclays, and UBS have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Certara, a company specializing in biosimulation software for drug discovery and development, shows a revenue growth of 1.03% as of September 30, 2023, but has a net margin of -57.22% and an ROE of -4.56%.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

NKTR

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to release its quarterly earnings report on March 4, 2024, with an expected EPS of $-0.21. Despite beating the EPS estimate last quarter by $0.01, NKTR's stock dropped by 8.76% the following day. Historically, the company's earnings performance has led to mixed stock price reactions. Currently trading at $0.71, NKTR shares have declined by 49.2% over the last year, indicating a bearish outlook among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

PCRX

Analysts have provided varied ratings for Pacira BioSciences (NASDAQ:PCRX) over the past three months, with a recent shift towards a more bullish stance. The average 12-month price target has been adjusted to $47.25, marking a 10.85% decrease. The company faces revenue challenges with a -2.11% decline over 3 months but exhibits strong financial health with exceptional net margin and ROE. Pacira BioSciences specializes in non-opioid pain management solutions, notably EXPAREL.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

META

The article provides an in-depth analysis of Meta Platforms (NASDAQ:META) within the Interactive Media & Services industry, comparing it to competitors based on financial metrics. Meta Platforms shows strong performance with a low PE ratio suggesting undervaluation, high PB and PS ratios indicating premium valuation, and superior ROE, EBITDA, gross profit, and revenue growth compared to industry averages. The company's low debt-to-equity ratio also highlights a strong financial position.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

EKSO

Ekso Bionics Holdings (NASDAQ:EKSO) is set to release its quarterly earnings report on Monday, 2024-03-04, with an estimated EPS of $-0.11. Historical data shows the company has previously beaten EPS estimates, leading to share price increases. Shares are currently trading at $1.9, up 33.25% over the last 52 weeks, indicating a positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

SCM

Stellus Cap Investment (NYSE:SCM) is scheduled to release its quarterly earnings report on March 4, 2024, with analysts expecting an EPS of $0.45. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing a subsequent drop in share price. Over the last year, SCM shares have declined by 16.93%, indicating a bearish outlook among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

RITM

Rithm Capital (NYSE:RITM) has seen a 49.14% increase in short interest since its last report, with 8.31 million shares sold short, representing 1.73% of its float. This indicates a bearish market sentiment, although it's below the peer group average of 6.58% short interest as a percentage of float. The article suggests that while increased short interest signals bearish sentiment, it can also be bullish under certain conditions.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm